Author: Eggener SE, Rumble RB, Armstrong AJ, Morgan TM, Crispino T, Cornford P, van der Kwast T, Grignon DJ, Rai AJ, Agarwal N, Klein EA, Den RB, Beltran H
Year: 2019
AGREE II score: Available
Developer organization: American Society of Clinical Oncology
Type of cancer: Genitourinary, Prostate
Patient population: Adult
Location: International
This is a clinical practice guideline for men with localized prostate cancer. The use of molecular biomarkers for the management of these patients is examined. The guideline specifically discusses patient selection, active surveillance, the identification of clinically significant disease, choosing postprostatectomy adjuvant versus salvage radiotherapy, and emerging questions such as the relative value of tissue biomarkers compared to magnetic resonance imaging (MRI).
AGREE II - Quality of Reporting Assessment:
Scope and purpose: 91.7%
Applicability: 50%
Stakeholder involvement: 77.8%
Editorial independence: 87.5%
Rigour: 82.3%
Clarity presentation: 91.7%
